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In addition to lipid-lowering and cardiovascular protective actions,
statins may have beneficial effects on insulin sensitivity. The objec-
tive of the present study was to evaluate the effect of simvastatin
therapy on insulin resistance and on leptin, adiponectin, and C-
reactive protein (CRP) levels, as compared to metformin, in over-
weight pre-diabetic subjects. Forty-one subjects with BMI >25 kg/m2
and impaired fasting glucose or impaired glucose tolerance were
randomized to take simvastatin, 20 mg/day (N = 20) or metformin, 1.7
g/day (N = 21) for 16 weeks. Blood samples for the determination of
metabolic, hormonal, and inflammatory parameters were obtained at
baseline and after each treatment. After metformin therapy, signifi-
cant reductions in mean BMI and waist circumference were observed,
and after simvastatin treatment LDL and triglyceride levels were
significantly reduced. Insulin resistance determined by the homeosta-
sis model assessment decreased only with metformin. Independently
of the type of medication, a significant decrease in CRP levels was
detected from baseline to the end of the study. CRP showed a mean
reduction of 0.12 ± 0.04 mg/dL (P = 0.002) over time. No change in
leptin or adiponectin levels was induced by any therapy. The data
suggest that a low dose of simvastatin does not affect insulin resis-
tance in overweight pre-diabetic subjects and has no effect on leptin or
adiponectin levels. Further studies including a larger sample size,
higher doses of statins, and a placebo control group are necessary to
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Introduction
The benefits of lipid-lowering therapy
for primary and secondary prevention of
cardiovascular events have been extensively
demonstrated, particularly concerning the
use of statins (1-3). Their beneficial effects
have been mainly attributed to the reduction
of circulating LDL-cholesterol levels and
oxidized LDL, and to the increase of col-
lagen content in the plaque matrix (4). These
actions retard the development of the ather-
oma and stabilize the plaque, minimizing the
atherogenic process and thromboembolic
events (4). Several studies have shown the
efficacy of statins in reducing cardiovascu-
lar mortality (3,5). Clinical trials in which
statins were used as secondary prevention
found the cardiovascular protective effect to
be even higher in the subset of type 2 dia-
betic subjects (6). As far as we know, a study
on the metabolic benefits of statins includ-
ing only pre-diabetic subjects has not been
conducted.
Abnormalities in glucose metabolism
such as insulin resistance and/or hyperin-
sulinemia have been considered to be inde-
pendent cardiovascular risk factors (7). It is
possible that part of the cardiovascular ben-
efits of statins for diabetic subjects may be
due to their influence on insulin sensitivity
in addition to their classical lipid-lowering
effect. This hypothesis has been previously
investigated and controversial results were
obtained (8,9). Using several techniques to
measure insulin resistance, some studies have
suggested that simvastatin might improve
insulin sensitivity (8-10). Among the pleio-
tropic effects of statins, anti-inflammatory
properties have been the most investigated
(11,12) and their cardiovascular protection
has also been attributed to such actions (12,
13). A reduction in the levels of adipocyto-
kines such as TNF-α induced by statin thera-
py (14) could be a possible mechanism im-
proving glucose metabolism in insulin-re-
sistant subjects. However, the impact of
statins on hormones implicated in insulin
sensitivity has been poorly investigated.
The relationship between insulin and
leptin (an adipose tissue-derived hormone)
levels is well known, the latter being in-
volved in the pathophysiology of insulin
resistance (15). Insulin-resistant obese sub-
jects commonly exhibited hyperleptinemia
that has been interpreted as a state of leptin
resistance (16). On the other hand, levels of
a more recently identified hormone - adipo-
nectin (17), also secreted by adipocytes, are
reduced in obesity and type 2 diabetes (16).
Additionally, adiponectin is associated with
low triglyceride and high HDL-cholesterol
levels independently of body weight (18). A
negative association of this hormone with C-
reactive protein (CRP) and fibrinogen has
been demonstrated (19). These anti-inflam-
matory effects of adiponectin are also typi-
cal of statin therapy, raising the hypothesis
that such agents could act, at least in part, via
adiponectin.
The effects of simvastatin on hormones
involved in glucose metabolism (insulin,
leptin and adiponectin) in pre-diabetic sub-
jects have not been investigated. Conversely,
the cardioprotective benefits of metformin
(20), as well as its potential to improve insu-
lin sensitivity and to prevent overt type 2
diabetes (21), have been well documented in
epidemiological studies.
The aim of the present study was to in-
vestigate the effects of a 16-week period of
simvastatin treatment on insulin sensitivity
and on leptin, adiponectin, and CRP levels,
as compared with metformin, in two subsets
of overweight pre-diabetic subjects. We hy-
pothesized that, after simvastatin therapy,
these insulin-resistant subjects could obtain
hormonal benefits similar to those expected
with metformin.
Subjects and Methods
Patients aged 18 to 70 years with a body
mass index (BMI) of 25 to 40 kg/m2 were
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recruited from the Metabolic Syndrome Out-
patient Clinic of the Federal University of
São Paulo. In order to include insulin-resis-
tant subjects, those with a diagnosis of im-
paired fasting glucose or impaired glucose
tolerance during an oral glucose tolerance
test were selected (22). Written informed
consent was obtained from all participants
and the study was approved by the Institu-
tional Ethics Committee. Exclusion criteria
were severe dyslipidemia (LDL-cholesterol
≥160 mg/dL and/or triglycerides ≥300 mg/
dL), unstable blood pressure (>140 x 90
mmHg), coronary artery disease, liver or
kidney failure, secondary causes of obesity,
allergy or adverse effects of simvastatin or
metformin, and current use of medications
known to affect inflammatory activity and/
or lipid and glucose metabolism (other than
the agents under investigation). No formal
sample calculation was done in advance.
Statistical power was calculated a posteriori
based on the results and main effects of the
drugs investigated. The power of interaction
effect was greater than 99.9% for LDL-cho-
lesterol and equal to 78.6% for fasting plasma
glucose. Of the 44 patients enrolled, 23 were
randomized to take metformin and 21 to take
simvastatin. Two patients discontinued met-
formin therapy due to adverse effects and
one simvastatin-treated patient was lost to
follow-up. The baseline characteristics of
the dropout subjects and those who com-
pleted the study were not significantly dif-
ferent (data not shown).
Study protocol
This interventional open-label study with
two parallel treatment groups - metformin or
simvastatin - had a duration of 18 weeks,
including a 2-week run-in period when pa-
tients received dietary counseling and were
encouraged to practice physical activity.
Screening laboratory tests included plasma
glucose (fasting and 2 h after a 75-g glucose
load), lipoproteins, aspartate aminotrans-
ferase, alanine aminotransferase, bilirubins,
electrolytes, thyroid-stimulating hormone,
and electrocardiogram. At randomization,
blood samples were obtained for plasma
glucose, lipid profile, CRP, insulin, leptin,
and adiponectin determinations. Patients
were then randomized (simple randomiza-
tion) to receive metformin (Glifage®) 850
mg, twice a day, or simvastatin (Clinfar®) 20
mg, once a day; medications were provided
by Merck S.A. (Rio de Janeiro, RJ, Brazil).
The laboratory tests were repeated after 16
weeks of each therapy.
BMI was calculated as weight (kg) di-
vided by height (m) squared; waist circum-
ference was obtained at the umbilicus level.
Blood pressure was measured with a stand-
ard sphygmomanometer after 5 min of rest
in the sitting position. Hypertension was
defined as systolic and/or diastolic blood
pressure levels ≥140 x 90 mmHg or the use
of antihypertensive medication.
Plasma glucose, bilirubins, enzymes, and
electrolytes were determined by routine
methods. Cholesterol contents of lipopro-
tein fractions and triglycerides were meas-
ured enzymatically and processed with an
automatic analyzer. High sensitivity CRP
was determined by a chemiluminescent im-
munometric assay (Immulite, DPC, Los
Angeles, CA, USA), with sensitivity of 0.01
mg/dL, intra-assay coefficient of variation
of 4.2-6.4%, and inter-assay coefficient of
variation of 4.8-10.0%. Patients with CRP
greater than 1 mg/dL were excluded from
the analysis of inflammatory parameters since
these levels denote clinical inflammation
(23). Sera were stored at -20°C for further
hormonal determinations. Insulin was deter-
mined by a monoclonal antibody-based im-
munofluorimetric assay (AutoDelfia, Perkin
Elmer Life Sciences Inc., Norton, OH, USA).
Insulin resistance was determined by the
homeostasis model assessment method ac-
cording to Matthews et al. (24) and insulin
sensitivity index (ISI0,120) was determined
by the method of Gutt et al. (25). Leptin and
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adiponectin were determined by radioim-
munoassay (Linco Research, St. Charles,
MO, USA) with sensitivities of 0.5 and 1.0
ng/mL, respectively. The intra- and inter-
assay CV was 3.4-8.3 and 3.0-6.2% for leptin
and 1.8-6.2 and 6.9-9.2% for adiponectin.
Statistical analysis
Data are reported as means ± SD for
numerical variables or as number and per-
cent for categorical variables. The paired
Student t-test was used to compare mean
clinical and laboratory data between sub-
groups of patients according to the type of
therapy. The effect of drugs over time was
assessed by analysis of variance (ANOVA)
for repeated measures. Correlation between
variables was tested by the Pearson coeffi-
cient and 95% confidence intervals are pre-
sented. The level of significance was set at α
= 0.05. Data analysis was performed using
the Statistical Analysis System (SAS) soft-
ware, version 8.02.
Results
Forty-one patients completed the study
and their main baseline characteristics are
detailed in Table 1. Except for a higher mean
BMI for the metformin-treated patients at
baseline, the simvastatin and metformin
groups were similar regarding sociodemo-
graphic data, frequency of hypertension and
glucose metabolism disturbances, as well as
mean values of blood pressure, fasting and
2-h plasma glucose, fasting insulin, leptin,
adiponectin, and CRP. Table 2 presents a
comparison between simvastatin and met-
formin delta values for the selected vari-
ables. As expected, when compared to
simvastatin, metformin therapy resulted in
significant reductions in mean BMI and fast-
ing plasma glucose, whereas simvastatin
treatment resulted in significantly reduced
total and LDL-cholesterol levels. Aspartate
aminotransferase and alanine aminotrans-
ferase did not change with either treatment
(data not shown). Independently of medica-
tion type, a significant decrease in CRP lev-
els was detected from baseline to the end of
the study. CRP showed a mean reduction of
0.12 ± 0.04 mg/dL (P = 0.002) over time.
The insulin resistance index as deter-
mined by homeostasis model assessment
decreased significantly only in metformin-
treated patients, whereas ISI0,120 remained
unchanged with both drugs (Table 2). Mean
leptin and adiponectin concentrations did not
change in either treatment group (Table 2).
Discussion
This study focused on poorly investi-
gated aspects of statin and metformin thera-
pies such as their impact on certain hor-
mones (leptin and adiponectin), as well as on
indices of insulin sensitivity. Since both
medications - simvastatin and metformin -
may have metabolic and cardiovascular ben-
efits beyond their classical actions on glu-
cose and lipid metabolism, the present study
Table 1. Baseline characteristics of patients treated with metformin or simvastatin for
16 weeks.
 Metformin (N = 21) Simvastatin (N = 20)
Men:women 0:21 3:17
Age (years) 48.6 ± 9.1 50.7 ± 8.2
Body mass index (kg/m2) 36.1 ± 0.8 33.8 ± 0.8*
Waist circumference (cm) 104.2 ± 2.2 102.2 ± 2.2
Hypertension (%) 61.9% 75.0%
Mean blood pressure (mmHg) 91.7 ± 10.3 97.5 ± 13.5
Disturbance of glucose metabolism (%)
Isolated IFG 4 (19%) 3 (15%)
Impaired glucose tolerance 17 (81%) 17 (85%)
Fasting plasma glucose (mg/dL) 105.0 ± 12.5 103.8 ± 11.5
2-h plasma glucose (mg/dL) 158.4 ± 26.8 158.9 ± 25.6
Fasting plasma insulin (µU/mL) 22.0 ± 20.4 15.0 ± 7.3
2-h plasma insulin (µU/mL) 131.2 ± 94.0 148.9 ± 85.8
Total cholesterol (mg/dL) 206.4 ± 36.3 211.1 ± 31.5
LDL-cholesterol (mg/dL) 126.8 ± 30.8 129.6 ± 26.2
HDL-cholesterol (mg/dL) 50.1 ± 13.8 48.0 ± 12.3
Triglycerides (mg/dL) 144.8 ± 73.4 167.4 ± 96.6
Data are reported as number, percent of patients or means ± SD. IFG = impaired
fasting glycemia.
*P < 0.05 compared to the metformin group (ANOVA for repeated measures).
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investigated possible hormonal effects that
could be useful for patients with mild meta-
bolic abnormalities. However, no medica-
tion was associated with changes in adipo-
nectin or leptin levels, nor did simvastatin
improve insulin sensitivity in the study sam-
ple. The expected benefit of metformin for
insulin resistance was detected. Our data
also confirmed previous evidence (12,13,20)
that both medications may have pleiotropic
effects, since reduction in CRP was observed.
In addition to the main mechanism by
which statins reduce cardiovascular risk (li-
pid-lowering effect), their ability to decrease
CRP could add important prognostic infor-
mation to the atherogenic process (26). CRP
appears to be the strongest novel cardiovas-
cular risk factor identified so far but also
hyperinsulinemia and/or insulin resistance
have been shown to be independently pre-
dictive of cardiovascular disease (7). A po-
tential link between atherosclerosis and dis-
turbance of glucose metabolism may involve
inflammatory factors. Whether any statin
plays a relevant role in insulin sensitivity in
insulin-resistant subjects has been poorly
investigated. This hypothesis was raised
based on the finding of a lower incidence of
diabetes in subjects under statin therapies in
epidemiological studies (27). However, the
findings of the present study did not support
such a hypothesis, despite the reduction in
the inflammatory marker CRP.
In contrast, many lines of evidence con-
firm that metformin improves insulin sensi-
tivity and prevents diabetes in high-risk sub-
jects (21). In the present study, we selected a
subset of patients who were supposed to
achieve great benefits from the attenuation
of insulin resistance. Overweight pre-dia-
betic patients are eligible for intervention in
order to minimize cardiovascular risk. This
was true for the subset treated with met-
formin in the present study, since reductions
in BMI, plasma glucose and insulin resis-
tance were observed. The lack of benefits for
glucose metabolism with simvastatin thera-
Table 2. Comparison of delta values (mean difference between final and baseline
values) of clinical and laboratory variables in the groups treated with simvastatin and
metformin.
Metformin         Simvastatin
Body mass index (kg/m2) 1.2 ± 0.3 0.3 ± 0.3*
Waist circumference (cm) 2.4 ± 0.8 0.2 ± 0.8
Mean blood pressure (mmHg) 0.3 ± 2.5 0.6 ± 2.7
Fasting plasma glucose (mg/dL) 5.8 ± 2.7 -5.1 ± 2.7*
Fasting insulin (µU/mL) 6.4 ± 3.1 -0.2 ± 3.2
HOMA-IR 1.9 ± 0.9 -0.3 ± 0.9*
ISI0,120 -4.1 ± 3.5 -1.8 ± 3.6
LDL-cholesterol (mg/dL) 4.4 ± 5.4 46.4 ± 5.5*
HDL-cholesterol (mg/dL) -4.0 ± 1.5 -3.0 ± 1.6
Triglycerides (mg/dL) 14.9 ± 12.1 28.3 ± 12.4
Total cholesterol (mg/dL) 4.0 ± 5.0 51.5 ± 5.1*
C-reactive protein (mg/dL) 0.2 ± 0.1 0.1 ± 0.1
Leptin (ng/mL) 14.5 ± 10.8 5.8 ± 11.0
Adiponectin (µg/mL) -0.1 ± 0.8 1.1 ± 0.9
Data are reported as mean ± SD. HOMA-IR = homeostasis model assessment of
insulin resistance; ISI0,120 = insulin sensitivity index.
*P < 0.05 compared to the metformin group (ANOVA for repeated measures).
py could be attributed to limitations of the
study design. The 20-mg dose may have
been too low to demonstrate an improve-
ment in insulin resistance; additionally, the
techniques employed to measure insulin sen-
sitivity may have been inappropriate consid-
ering the sample size. As a consequence of
this negative finding, we were unable to
investigate the possible involvement of hor-
mones (leptin and adiponectin) in the ben-
efits of statin for glucose metabolism, as
proposed.
Compliance with the medications did not
seem to be a limitation, since the main ex-
pected effects of the drugs (reduction in
LDL-cholesterol by simvastatin and in plas-
ma glucose by metformin) were verified.
Therefore, we cannot exclude the possibility
that simvastatin has truly no impact on insu-
lin resistance. In type 2 diabetic subjects,
some investigators found that simvastatin
combined with ACE inhibitors or angio-
tensin receptor antagonists increased adipo-
nectin levels and insulin sensitivity, but not
when administered as monotherapy (28,29).
Our findings are in the same line of other
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reports which did not show changes in leptin
or adiponectin levels following isolated statin
therapy in dyslipidemic or type 2 diabetic
subjects (28-30).
The expected action of metformin in im-
proving insulin sensitivity was observed in
the present study. Despite a metformin-in-
duced weight loss and probably fat mass
loss, this medication did not induce changes
in leptin concentrations. Contrasting find-
ings were observed in other studies which
detected a reduction in leptin levels in obese
type 2 diabetic patients (31). Our inability to
demonstrate an effect of metformin therapy
on leptin and adiponectin levels in metabolic
disturbed subjects is in agreement with other
studies (32-34). In fact, mechanisms under-
lying the improvement in insulin resistance
induced by metformin seem to depend es-
sentially on hepatic actions but not on adi-
pose tissue, the main source of the latter
hormones.
The lack of a placebo control group could
be seen as a weak point of the present study.
In fact, such group could contribute to reach-
ing a more definite interpretation of the mech-
anism of action of the drugs. However, it
should be mentioned that the original objec-
tive of the present study was to compare drugs
with distinct mechanisms of action on me-
tabolism. The sample size could be a second
limitation to adequately evaluate the impact of
the drugs on hormonal parameters.
Our data neither support that low-dose
simvastatin could affect insulin resistance in
overweight pre-diabetic subjects, nor show
any effect of the drug on leptin or adiponectin
levels. Therefore, the reported cardiovascu-
lar protective effect of statins seems to be
independent of benefits for glucose metabo-
lism. Attenuation of the inflammatory pro-
cess induced by statin and metformin could
be an additional mechanism improving car-
diovascular risk. Further studies including
larger samples and higher daily doses of
medications are necessary.
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